Baxter to Acquire Hillrom for ~$10.5B

 Baxter to Acquire Hillrom for ~$10.5B

Shots:

  • Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s closing price of $124 and a total enterprise value of ~ $12.4B, including the assumption of debt. The acquisition is expected to be closed in early 2022
  • The acquisition will expand access to Hillrom’s portfolio globally and accelerate the companies’ expansion into digital and connected care solutions at home or in other care settings
  • Baxter to get a broader array of medical products and services to patients and clinicians across the continuum of care. The companies expect about $250M in annual cost synergies over the next three yrs.

Click here to­ read full press release/ article | Ref: Businesswire | Image: Baxter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post